Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options

Area of Science:

• Regenerative Medicine
• Cell Therapy Manufacturing
• Biotechnology

Background:

• Mesenchymal stromal cells (MSCs) are utilized in advanced therapy medicinal products (ATMPs) for diverse clinical applications.
• MSC sources vary, including donor tissues, induced pluripotent stem cells, and embryonic stem cells.
• Heterogeneity in ATMPs can affect product identity and potency, impacting clinical outcomes.

Purpose of the Study:

• To review the challenges associated with Mesenchymal Stromal Cell (MSC)-based advanced therapy medicinal products (ATMPs).
• To highlight the impact of manufacturing variability on product identity, potency, and clinical trial success.
• To emphasize the need for standardized manufacturing criteria for MSCs in regenerative medicine.

Main Methods:

• Literature review of current practices in MSC isolation and manufacturing.
• Analysis of factors contributing to ATMP heterogeneity.
• Discussion of the implications of variability for clinical translation.

Main Results:

• Significant variability exists in MSC sources and manufacturing methods.
• Product heterogeneity poses a risk to the identity, potency, and efficacy of MSC-based ATMPs.
• Current manufacturing processes lack universally established minimal criteria.

Conclusions:

• Standardized manufacturing criteria for MSCs are essential for ensuring product consistency and therapeutic efficacy.
• Addressing manufacturing variability will improve the reliability of MSC-based ATMPs in clinical trials.
• Establishing minimal criteria will facilitate the advancement of regenerative medicine through robust cell-based therapies.